| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,733 | -4,412 | -3,262 | -4,238 |
| Depreciation | 2 | 3 | 4 | 7 |
| Share-based payment arrangement, noncash expense | 345 | 38 | 38 | 58 |
| Represent the amount of non cash loss upon entering transactions | NaN | 0 | NaN | NaN |
| Non-cash financial expenses | -4 | -50 | -294 | NaN |
| Loss (gain) on disposal of property and equipment | NaN | 0 | NaN | NaN |
| Other noncash expense | NaN | NaN | NaN | 310 |
| Loss from lease termination | NaN | 0 | 0 | NaN |
| Increase in prepaid expenses | 959 | -1,169 | 56 | 717 |
| Decrease (increase) in other current assets | 47 | 2 | -16 | 1 |
| Increase (decrease) in accounts payable, trade | 125 | -159 | 254 | -237 |
| Increase (decrease) in operating lease liability | -4 | -4 | -2 | 1 |
| Increase (decrease) in employee related liabilities | -319 | 158 | 93 | -14 |
| Increase (decrease) in accrued liabilities | NaN | 102 | NaN | NaN |
| Increase (decrease) in other accounts payable and accrued liabilities | -19 | NaN | 88 | -129 |
| Net cash provided by (used in) operating activities | -3,646 | -3,016 | -2,843 | -4,960 |
| Investment in long-term deposits | NaN | 5 | NaN | NaN |
| Purchase of property and equipment | 0 | 2 | 0 | 7 |
| Net cash provided by (used in) investing activities | 0 | -7 | 0 | -7 |
| Represents the amount of prepaid of issuance cost related to at the market offering | NaN | 43 | 31 | NaN |
| Proceeds from issuance of common stock | 83 | NaN | 0 | NaN |
| Proceeds from stock options exercised | NaN | 0 | NaN | 0 |
| Cash acquired in excess of payments to acquire business | NaN | 0 | 0 | NaN |
| Represents proceeds from issuance of ordinary shares upon public offering | 0 | 0 | 6,000 | 5,000 |
| Proceeds from issuance initial public offering | 0 | -132 | -653 | -745 |
| Proceeds from warrant exercises | 0 | 0 | 1,780 | 864 |
| Represents proceeds from issuance of ordinary shares upon warrants inducement | 0 | 0 | 1,760 | 3,276 |
| Issuance costs related to warrants inducement transactions | 0 | 46 | 232 | 462 |
| Represent the value of payment of underwriters promissory note | 0 | 1,392 | 0 | -696 |
| Net cash provided by (used in) financing activities | 83 | -221 | 8,624 | 7,237 |
| Cash, cash equivalents, restricted cash, and restricted cash equivalents, period increase (decrease), excluding exchange rate effect | -3,563 | -3,244 | 5,781 | 2,270 |
| Effect of exchange rate on cash, cash equivalents, restricted cash, and restricted cash equivalents, continuing operations | -14 | -5 | 3 | NaN |
| Balance of cash, cash equivalents and restricted cash at end of period | 6,075 | 1,270 | 1,270 | NaN |
| Balance of cash, cash equivalents and restricted cash at end of period | 2,498 | 6,075 | 9,324 | NaN |
Silexion Therapeutics Corp (SLXNW)
Silexion Therapeutics Corp (SLXNW)